Entropy Neurodynamics (ASX: ENP) announced a significant clinical trial update for its TRP-8803 program, alongside progress in Cohort 2 enrolment and receipt of R&D tax incentives.
The third patient in the TRP-8803 IV-infused psilocin binge eating disorder (BED) trial completed two scheduled infusions on 24 March 2026 and 9 April 2026.
All patients dosed to date in the trial have now achieved a psychedelic response.
Crucially, clinicians were able to replicate the onset, depth, and duration of this psychedelic response, suggesting a controlled therapeutic potential for the drug.
Dosing for Cohort 1 is nearing completion, while Cohort 2 enrolment is advanced with four patients already signed up.
Clinical Momentum and Trial Progression
The trial is designed to include 12 patients across two six-person cohorts.
Each patient receives two doses 14 days apart, coupled with supportive therapy.
Cohort 1 is utilising a mid-range therapeutic dose, and Cohort 2 will explore an alternate dosing regimen, informed by the results from Cohort 1.
The primary endpoint for the trial focuses on assessing safety and tolerability over a 12-week observation period following the first dosing session.
Financial Runway Strengthened
Entropy Neurodynamics recently received a FY25 Australian Government R&D Tax Incentive refund of approximately A$1.7 million.
These proceeds are intended to fund the ongoing advancement of TRP-8803 and other clinical development programs.
The company's cash position was materially increased to A$6,425,780 at 31 December 2025 following prior placements and non-dilutive funding initiatives.
These include an R&D loan and a FY24 R&D Tax Incentive receipt.
Platform IP and Biomarker Development
An Australian patent was recently granted, securing method-level intellectual property (IP) protection for TRP-8803's IV administration through 2042.
This patent covers a precision-controlled, two-phase IV dosing regimen, emphasising reproducible onset (within five to 30 minutes), controlled maintenance infusion, and the ability for clinicians to stop treatment by ending the infusion.
Additionally, Entropy Neurodynamics has an exclusive agreement with professors from Imperial College London to develop a real-time EEG-based 'brain entropy' biomarker platform.
This aims to predict and optimise therapeutic outcomes across TRP-8803 development.
Outlook
Entropy Neurodynamics continues to demonstrate positive clinical momentum for its TRP-8803 program with evidence of repeatable psychedelic effects.
Coupled with strengthened financial footing through R&D tax incentives and a robust IP portfolio, the company appears well-positioned for continued development.
However, ongoing funding needs and early-stage clinical risks remain factors to monitor.
